MDT

86.16

-0.16%↓

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

MDT

86.16

-0.16%↓

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

MDT

86.16

-0.16%↓

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

MDT

86.16

-0.16%↓

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

MDT

86.16

-0.16%↓

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Open

1.29 -4.44

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.27

Max

1.34

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.7M -24M
EPS	-0.354
Angestellte	49
EBITDA	-5.3M -28M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+103.82% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-8.4M 73M
Vorheriger Eröffnungskurs	5.73
Vorheriger Schlusskurs	1.29

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Apr. 2026, 23:17 UTC

Ergebnisse

Samsung Forecasts Record First-Quarter Operating Profit

6. Apr. 2026, 23:00 UTC

Heiße Aktien

Stocks to Watch: Health Insurers, Mawson, Owlet

6. Apr. 2026, 22:13 UTC

Wichtige Markttreiber

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6. Apr. 2026, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6. Apr. 2026, 17:09 UTC

Wichtige Markttreiber

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6. Apr. 2026, 16:56 UTC

Wichtige Nachrichtenereignisse

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6. Apr. 2026, 14:47 UTC

Wichtige Markttreiber

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6. Apr. 2026, 23:58 UTC

Market Talk

Wichtige Nachrichtenereignisse

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6. Apr. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6. Apr. 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6. Apr. 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6. Apr. 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6. Apr. 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6. Apr. 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6. Apr. 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6. Apr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6. Apr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Apr. 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. Apr. 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6. Apr. 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6. Apr. 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6. Apr. 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6. Apr. 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6. Apr. 2026, 18:36 UTC

Akquisitionen, Fusionen, Übernahmen

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. Apr. 2026, 17:59 UTC

Market Talk

Wichtige Nachrichtenereignisse

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6. Apr. 2026, 17:13 UTC

Akquisitionen, Fusionen, Übernahmen

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. Apr. 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6. Apr. 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Apr. 2026, 14:59 UTC

Ergebnisse

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

103.82% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 103.82%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.